Measurements of C-reactive protein (CRP) and nerve-growth-factor (NGF) concentrations in serum and urine samples of dogs with neurologic disorders

Background: Overactive bladder (OAB) is a clinical syndrome characterized by a combination of symptoms including urgency, frequency, and nocturia, with or without urinary incontinence. Overactive bladder has a high prevalence especially in those of an older age and women, with diagnosis depending on the patient’s symptoms. This study aims to assess brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and high sensitivity C-reactive protein (HSCRP) in urine as biomarkers in OAB. Methods: Studies were searched from Pubmed, Science Direct, Wiley Online Library, and Google Scholar. All studies assessing BDNF, NGF, and HSCRP in urine in OAB patients were included. The standardized mean difference (SMD) and 95% confidence intervals (CI) were then calculated. Results: A total of 85 studies were included with a total of 11,483 subjects (6,885 OAB patients and 4,598 controls). Based on data analysis results, urinary NGF/Creatinine (NGF/Cr) and NGF level in OAB patients were significantly higher than control (SMD = 1.00, 95%CI = 0.80-1.20, P<0.00001; and SMD = 1.11, 95%CI = 0.79-1.43, P<0.00001). NGF/Cr level was found higher in OAB with incontinence (OAB wet) compared with OAB without incontinence (OAB dry) (SMD = 0.41, 95%CI = 0.23-0.60, P<0.0001), and decreased after treatment (SMD = 0.76, 95%CI = 0.49-1.03, P<0.00001). Urinary BDNF/Cr level was significantly higher in OAB patients compared with controls (SMD = 1.97, 95%CI = 1.14-2.79, P<0.00001), and also decreased significantly after treatment (SMD = 0.75, 95%CI = 0.42-1.08, P<0.00001). The level of HSCRP was significantly higher in OAB patients when compared with controls (SMD = 0.38, 95%CI = 0.12-0.64, P<0.004). Conclusions: The level of BDNF/Cr, NGF/Cr, NGF, and HSCRP in urine were found higher in OAB compared with controls, which means they may be used as a biomarkers for OAB.

Download Full-text

The diagnostic value of nerve growth factor and c-reactive protein in patients with interstitial cystitis / painful bladder syndrome

Urologicheskie vedomosti ◽

10.17816/uroved10161-66 ◽

2020 ◽

Vol 10 (1) ◽

pp. 61-66

Author(s):

Rashad F. Sholan

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Interstitial Cystitis ◽

Diagnostic Value ◽

Painful Bladder Syndrome ◽

Control Group ◽

C Reactive Protein ◽

Nerve Growth ◽

Reactive Protein ◽

Painful Bladder

Objective: to determine the diagnostic value of nerve growth factor (NGF) and C-reactive protein (CRP) in patients with interstitial cystitis / painful bladder syndrome (IC/BPS). Material and methods. 44 patients with IC/BPS (main group) and 20 volunteers (control group) were examined. The average age of the patients of the main group was 46.4 13.9 years, the control group 35.3 9.7 years. Cystoscopy and hydrodistension of the bladder were performed. The severity of pain was evaluated on a visual analogue scale (VAS). The concentration of NGF was determined in the blood by the method of ELISA, CRP by the immunoturbidimetric method. Results. The average total score on the VAS scale was 5.47 0.91, mild pain (24 points) was noted by 20.4%, moderate pain (56 points) 54.5%, severe pain (78 points) 25.0% of patients. Diffuse bleeding of the bladder mucosa in 45.4% of cases was observed. In IC/BPS patients the average NGF level was 11.23 8.22 ng/ml, CRP 3.56 1.66 mg/l. The concentration of NGF exceeded the control level by 22.7% (p 0.05), CRP by 71.3% (p = 0.015). The correlation coefficient of NGF with CRP was r = + 0.179 (p = 0.42), and the determination coefficient was R2 = 0.032. Conclusion. Identified statistically significantly increased levels of NGF and CRP in the blood serum of IC/BPS patients confirm the presence of a systemic inflammatory reaction. A weak direct correlation is determined between NGF and CRP in patients with IC/BPS patients. The determination of serum NGF and CRP in combination with clinical data can be used to diagnose IC/ BPS.

Download Full-text

MP-03.09: The levels of serum C-reactive protein and urinary nerve growth factor in patients with OAB and IC/BPS

Urology ◽

10.1016/j.urology.2010.07.384 ◽

2010 ◽

Vol 76 (3) ◽

pp. S25

Author(s):

Y. Tseng ◽

S. Chung ◽

H. Liu ◽

H. Kuo

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

C Reactive Protein ◽

Nerve Growth ◽

Reactive Protein

Download Full-text

Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder

Clinical Medicine Insights Urology ◽

10.1177/1179561119864907 ◽

2019 ◽

Vol 12 ◽

pp. 117956111986490

Author(s):

Sameer Trivedi ◽

Pranab Patnaik ◽

Yashpal Ramole ◽

Faiz Ahmed Khan ◽

Ragini Srivastava ◽

...

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Overactive Bladder ◽

Therapeutic Potential ◽

Control Group ◽

C Reactive Protein ◽

Nerve Growth ◽

Protein Levels ◽

Reactive Protein ◽

The Mean

Background: This study compared urinary and serum nerve growth factor levels and serum C-reactive protein levels in patients with overactive bladder, before and after treatment with antimuscarinic agents, to evaluate their diagnostic and therapeutic importance. Methods: This was a prospective case-control study conducted between February 2014 and December 2014 which included patients with a confirmed diagnosis of overactive bladder (overactive bladder group) and healthy controls (control group). All patients visiting urology out-patient department with urgency, frequency, and urge incontinence were assessed for overactive bladder and, if eligible, were enrolled in the study. Biomarkers were evaluated before in both groups and after antimuscarinic treatment in the overactive bladder group. Results: Overall, 80 participates were enrolled (overactive bladder, n = 40; control, n = 40). The mean age was not different between the two groups (overactive bladder, 48.6 years; control, 46.9 years [ P = 1.01]) and females were more in both the groups (60% and 55%, respectively). The majority (70%) of patients presented with frequency and urgency. After 3 months of treatment with antimuscarinics, the mean overactive bladder symptom score decreased significantly from 8.4 to 4.85 ( P < .001). The mean urinary and serum nerve growth factor levels and serum C-reactive protein levels also decreased significantly from baseline after 3 months of treatment with antimuscarinics (24.78 pg/mL, 22.46 pg/mL, 0.89 mg/L, respectively; P < .0001). Conclusions: Measurement of urinary and serum nerve growth factor levels has diagnostic and therapeutic potential in patients with overactive bladder.

Download Full-text